Idasanutlin. MDM2 (Hdm2) inhibitor, Treatment of acute myeloid leukemia, Hematological cancer therapy

2018 ◽  
Vol 43 (2) ◽  
pp. 87
Author(s):  
J. Gras
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cancer Therapy ◽  
Myeloid Leukemia ◽  
Hematological Cancer ◽  
Inhibitor Treatment ◽  
Acute Myeloid

Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia

2021 ◽  
Vol 100 ◽  
pp. 106494
Author(s):  
Diego Adrianzen-Herrera ◽  
Ximena Jordan-Bruno ◽  
Katherine A. Devitt ◽  
Joanna L. Conant ◽  
Juli-Anne Gardner
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Clonal Evolution ◽  
Refractory Acute Myeloid Leukemia ◽  
Inhibitor Treatment ◽  
Acute Myeloid

Combination of vaccine-strain measles and mumps virus synergistically kills a wide range of human hematological cancer cells: Special focus on acute myeloid leukemia

2014 ◽  
Vol 354 (2) ◽  
pp. 272-280 ◽  
Author(s):  
Li Feng Zhang ◽  
Darren Qian Cheng Tan ◽  
Anand D. Jeyasekharan ◽  
Wen Son Hsieh ◽  
Anh Son Ho ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cancer Cells ◽  
Vaccine Strain ◽  
Myeloid Leukemia ◽  
Mumps Virus ◽  
Special Focus ◽  
Hematological Cancer ◽  
Wide Range ◽  
Acute Myeloid

scholarly journals Validation of the Functional Assessment of Cancer Therapy–Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy

Cancer ◽  
2020 ◽  
Vol 126 (15) ◽  
pp. 3542-3551
Author(s):  
John Devin Peipert ◽  
Susan E. Yount ◽  
Fabio Efficace ◽  
Christina Loefgren ◽  
Renee Pierson ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Myeloid Leukemia ◽  
Intensive Therapy ◽  
Acute Myeloid

SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia

Blood ◽  
2014 ◽  
Vol 124 (1) ◽  
pp. 121-133 ◽  
Author(s):  
Daniel Sasca ◽  
Patricia S. Hähnel ◽  
Jakub Szybinski ◽  
Kaml Khawaja ◽  
Oliver Kriege ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Genotoxic Stress ◽  
Protein Levels ◽  
Activating Mutations ◽  
Key Points ◽  
P53 Activation ◽  
Inhibitor Treatment ◽  
Acute Myeloid

Key Points SIRT1 is highly expressed in subsets of patients with acute myeloid leukemia harboring activating mutations in signaling pathways and is regulated at the protein levels. Targeting SIRT1 sensitizes leukemic blast to tyrosine kinase inhibitor treatment or chemotherapy via restoration of p53 activity.

Sign in / Sign up

Export Citation Format

Share Document